| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKYA | Common Stock | Options Exercise | $1,515 | +5,000 | +6.2% | $0.3030* | 85,000 | 07 Sep 2022 | Direct | |
| transaction | AKYA | Common Stock | Sale | $64,170 | -5,000 | -5.9% | $12.83 | 80,000 | 07 Sep 2022 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AKYA | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -5,000 | -1.4% | $0.000000 | 343,129 | 07 Sep 2022 | Common Stock | 5,000 | $0.3030 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated May 16, 2022. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at pri ces ranging from $12.12 to $12.99, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. |
| F3 | The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one -fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, subject to reporting person's continuous employment. |